Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1996-12-18
1998-11-03
Chambers, Jasemine C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 4, 514 44, 530303, 4351723, A61K 3828, C12N 1500, C12N 1587
Patent
active
058308520
ABSTRACT:
The invention is based on the discovery of a pharmaceutical preparation for use in gene therapy which includes a therapeutic nucleic acid associated with Insulin-NHCO--CH.sub.2 --O--N.dbd.CH--C-Lys.sub.18 -Cys(S-Pyridyl)-OH in combination with a pharmaceutically acceptable carrier.
REFERENCES:
patent: 5166320 (1992-11-01), Wu et al.
Rose et al., Peptides 198820:274-276 (1989).
Vilaseca et al., Bioconjugate Chemistry 4:515-520 (1993).
Chen et al., 1994, Galactosylated histone-mediated gene transfer and expression, Human Gene Therapy 5: 429-435.
Graham and van der Eb, 1973, A new technique for the assay infectivity of human adenovirus 5 DNA, Virology 52: 456-467.
Huckett et al., 1990, Evidence for targeted gene transfer by receptor-mediated endocytosis, Biochem. Pharm. 40: 253-263.
Kaneda et al., 1987, The improved efficient method for introducing macromolecules into cells using HVJ (Sendai virus) liposomes with gangliosides,Exp. Cell Res. 173: 56-69.
Keown, et al., 1990, Methods for introducing DNA into mammalian cells, Methods Enzymol. 185: 527-537.
Kucherlapati and Skoultchi, 1984, Introduction of purified genes ito mammalian cells, Crit. Rev. Biochem. 16:349-379.
Loyter and Volsky, 1982, Reconstituted Sendai virus envelopes as carriers for the introduction of biological material into cells, Cell Sur. Rev. 8:215-266.
Machy et al., 1988, Gene transfer from targeted liposomes to specific lymphoid cells by eletroporation, Proc. Natl. Acad. Sci. USA 85:8027-8031.
Midoux et al., 1993, Specific gene transfer mediated by lactosylated poly-L-lysine into hepatoma cells, Nucleic Acids Res. 21:871-878.
Rosencranz et al., 1992, Receptor-mediated endocytosis and nuclear transport of a transfecting DNA construct, Exp. Cell Res. 199:323-329.
Trubetskoy et al., 1992, Use of N-terminal modified poly(L-lysine)-antibody conjugate as a carrier for targeted gene delivery in mouse lung endothelial cells, Bioconjugate Chem. 3: 323-327.
Wigler et al., 1979, Transformation of mammalian cells with genes from procaryotes and eucaryotes, Cell 16:777-785.
Wu and Wu, 1987, Receptor-mediated in vitro gene transformation by a soluble DNA carrier system,J. Biol. Chem. 262: 4429-4432.
Orkin et al. Report and Recommendations of the panel to assess the NIH investment in research on gene therapy. Distributed by the National Institutes of Health, Bethesda, MD, Dec. 7, 1995.
Gaertner Hubert F.
Offord Robin E.
Rose Keith
Thatcher David R.
Chambers Jasemine C.
Clark Deborah J.R.
Cobra Therapeutics, Ltd.
Williams Kathleen M.
LandOfFree
Compositions for insulin-receptor mediated nucleic acid delivery does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions for insulin-receptor mediated nucleic acid delivery, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for insulin-receptor mediated nucleic acid delivery will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-689106